Orthopaedics and cardiology groups start to improve in terms of sales per employee, but Covid test makers do better still.
The group has finally revalued its troubled sleep franchise. So what now?
And some diagnostics groups are forecast to actually cut R&D outlay this year as the pandemic eases.
Medtronic, Siemens and Stryker are all expected to seize greater market share, while Roche slides down the rankings.
Roche had the most innovative approvals over the last five years – but took second place in terms of speed.
Whether sitting on a pile of cash or guarding against growing pressures, acquisitions are the answer.
Big-cap device makers on European exchanges did nicely in 2021, whereas their US-listed brethren had a harder time.
Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.
Diagnostics companies enjoy notable uplift in sales; elsewhere, spinouts could shape the future.